HARPOON THERAPEUTICS INC's ticker is HARP and the CUSIP is 41358P106. A total of 63 filers reported holding HARPOON THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $80,989 | -34.2% | 111,601 | -11.8% | 0.00% | – |
| Q3 2022 | $123,000 | -69.2% | 126,570 | -39.4% | 0.00% | – |
| Q2 2022 | $399,000 | -50.3% | 208,920 | +29.3% | 0.00% | – |
| Q1 2022 | $803,000 | -5.2% | 161,567 | +44.1% | 0.00% | – |
| Q4 2021 | $847,000 | +22.8% | 112,100 | +28.3% | 0.00% | – |
| Q3 2021 | $690,000 | -77.7% | 87,398 | -60.8% | 0.00% | -100.0% |
| Q2 2021 | $3,094,000 | +234.5% | 223,039 | +404.6% | 0.00% | – |
| Q1 2021 | $925,000 | +71.9% | 44,203 | +36.4% | 0.00% | – |
| Q4 2020 | $538,000 | -3.9% | 32,418 | -1.7% | 0.00% | – |
| Q3 2020 | $560,000 | -39.4% | 32,983 | -40.7% | 0.00% | – |
| Q2 2020 | $924,000 | +463.4% | 55,630 | +403.2% | 0.00% | – |
| Q4 2019 | $164,000 | -44.0% | 11,055 | -48.5% | 0.00% | – |
| Q3 2019 | $293,000 | +5.4% | 21,450 | -26.9% | 0.00% | – |
| Q1 2019 | $278,000 | – | 29,356 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| New Leaf Venture Partners, L.L.C. | 3,156,699 | $15,689,000 | 7.73% |
| MPM ASSET MANAGEMENT LLC | 3,131,388 | $15,563,000 | 5.32% |
| MPM BioImpact LLC | 3,196,707 | $15,888,000 | 4.26% |
| ACUTA CAPITAL PARTNERS, LLC | 497,500 | $2,473,000 | 1.16% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 151,445 | $2,771,000 | 0.62% |
| Orbimed Advisors | 3,039,508 | $15,106,000 | 0.24% |
| Artal Group S.A. | 1,000,000 | $4,970,000 | 0.21% |
| Cormorant Asset Management, LP | 540,600 | $2,687,000 | 0.21% |
| DAFNA Capital Management LLC | 105,163 | $523,000 | 0.14% |
| Ikarian Capital, LLC | 117,009 | $582,000 | 0.08% |